Companies Mesa Laboratories
Mesa Laboratories (MLAB): executive pay, fiscal 2026
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Mesa Laboratories’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers37th pct.Of 19 peer CEOs
CEO pay, last three years
- $5,435,566FY2024
- $6,599,891FY2025
- $6,643,208FY2026
CEO total pay was $6,643,208 in fiscal 2026, up from $6,599,891 in fiscal 2025.
FY2026: salary $808,846 · bonus $0 · stock awards $4,700,017 · option awards $0
Executives and directors
Frequently asked questions
Who was the highest-paid executive at Mesa Laboratories in fiscal 2026?
As disclosed, Gary Owens (Former CEO and President) was the highest-paid executive at Mesa Laboratories in fiscal 2026, with total compensation of $6,643,208.
How does Mesa Laboratories's chief executive pay compare to its disclosed peer group?
As disclosed, Gary Owens's total compensation ranked at the 37th percentile of Mesa Laboratories's disclosed peer group.
What is Mesa Laboratories's CEO-to-median employee pay ratio?
As disclosed, Mesa Laboratories's CEO-to-median employee pay ratio was 79:1.
How did shareholders vote on Mesa Laboratories's executive compensation?
As disclosed, 96.93% of shareholders supported Mesa Laboratories's executive compensation in the latest say-on-pay vote.
How much does Mesa Laboratories spend in total on board compensation for fiscal 2026?
As disclosed, Mesa Laboratories reported total board compensation of $1,585,000 for fiscal 2026.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Gary Owens | $808,846 | $0 | $4,700,017 | $0 | $1,120,000 | $0 | $14,345 | $6,643,208 |
| Former CEO and President | ||||||||
| John Sakys | 498,385 | 0 | 1,550,150 | 0 | 408,750 | 0 | 14,258 | 2,471,543 |
| VP and Chief Financial Officer | ||||||||
| Brian Archbold | 436,962 | 0 | 1,400,080 | 0 | 331,250 | 0 | 14,226 | 2,182,518 |
| SVP of Operations and Continuous Improvement | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2026 total | FY2025 total | FY2024 total | Δ FY2025→2026 |
|---|---|---|---|---|
| Gary Owens | $6,643,208 | $6,599,891 | $5,435,566 | ↑ +43,317 |
| John Sakys | 2,471,543 | 2,424,110 | 1,943,292 | ↑ +47,433 |
| Brian Archbold | 2,182,518 | 2,134,556 | 1,622,620 | ↑ +47,962 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Compensation Committee oversees the executive compensation program for our NEOs. The program is designed to attract, retain, and motivate exceptional talent in a highly competitive market environment, while aligning executive team incentives with Mesa's long-term value creation for shareholders.
| CEO STI target (% of salary) | 110% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Frederic W. Cook & Co, Inc. |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2026
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| John Sakys | PSU | 2025-06-15 | 3,893 | 7,785 | — | 15,570 | $775,075 |
| Gary Owens | PSU | 2025-06-15 | 11,802 | 23,604 | — | 47,208 | 2,350,014 |
| Gary Owens | RSU | 2025-06-15 | — | — | 24,659 | — | 2,350,003 |
| Brian Archbold | RSU | 2025-06-15 | — | — | 7,346 | — | 700,074 |
| John Sakys | RSU | 2025-06-15 | — | — | 8,133 | — | 775,075 |
| Brian Archbold | PSU | 2025-06-15 | 3,516 | 7,031 | — | 14,062 | 700,006 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| John Sakys | $775,075 | $775,075 | $0 | 50.0% |
| Gary Owens | 2,350,003 | 2,350,014 | 0 | 50.0% |
| Brian Archbold | 700,074 | 700,006 | 0 | 50.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2026
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Brian Archbold | RSU | 844 | — | $74,626 |
| John Sakys | RSU | 1,036 | — | 91,603 |
| Brian Archbold | Option | 1,511 | 131.67 | — |
| John Sakys | Option | 1,854 | 131.67 | — |
| Brian Archbold | RSU | 1,859 | — | 164,373 |
| John Sakys | RSU | 2,281 | — | 201,721 |
| Brian Archbold | PSU | 2,824 | — | 249,698 |
| John Sakys | PSU | 3,138 | — | 277,462 |
| Gary Owens | RSU | 3,300 | — | 291,786 |
| Brian Archbold | PSU | 3,516 | — | 310,885 |
| John Sakys | PSU | 3,893 | — | 344,175 |
| Brian Archbold | RSU | 4,960 | — | 438,563 |
| John Sakys | RSU | 5,511 | — | 487,283 |
| Gary Owens | Option | 5,905 | 131.67 | — |
| Gary Owens | RSU | 7,280 | — | 643,680 |
| Brian Archbold | RSU | 7,346 | — | 649,533 |
| Brian Archbold | PSU | 7,516 | — | 664,565 |
| John Sakys | PSU | 8,352 | — | 738,484 |
| Gary Owens | PSU | 9,621 | — | 2,283,256 |
| Gary Owens | RSU | 11,559 | — | 1,022,047 |
| Gary Owens | PSU | 11,802 | — | 1,043,533 |
| John Sakys | RSU | 16,448 | — | 1,454,332 |
| Gary Owens | RSU | 16,900 | — | 1,494,298 |
| Gary Owens | RSU | 24,659 | — | 2,180,349 |
| Gary Owens | PSU | 25,608 | — | 2,264,259 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| John SullivanNot independent · Board Chair | $105,000 | $190,000 | $0 | — | $0 | $295,000 |
| Jennifer AlltoftIndependent · Audit · Nominating and Governance (Chair) | 70,000 | 190,000 | 0 | — | 0 | 260,000 |
| Tony TripenyIndependent · Audit (Chair) · Compensation | 70,000 | 190,000 | 0 | — | 0 | 260,000 |
| Mark CaponeIndependent · Audit · Compensation (Chair) | 70,000 | 190,000 | 0 | — | 0 | 260,000 |
| Shiraz LadiwalaIndependent · Lead Independent Director · Nominating and Governance | — | 260,000 | 0 | — | 0 | 260,000 |
| Shannon HallIndependent · Compensation · Nominating and Governance | 60,000 | 190,000 | 0 | — | 0 | 250,000 |
| Siddhartha KadiaEmployee director · Partial-year service · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $60,000 |
|---|---|
| Annual equity retainer | $190,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 10,000 / 10,000 |
| Stock ownership guideline | 3x annual retainer |
Total cost of the board
| Component | FY2026 |
|---|---|
| Cash retainers and fees | $375,000 |
| Equity awards (grant-date value) | $1,210,000 |
| All other compensation | $0 |
| Total cost of the board | $1,585,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Mesa Laboratories as a peer
Companies that benchmark against MLAB
15 companies name MLAB as a compensation peer
- Adaptive Biotechnologies CorpADPTFY2025
- BIOLIFE SOLUTIONS INCBLFSFY2024
- Cryoport, Inc.CYRXFY2025
- Cytek Biosciences, Inc.CTKBFY2025
- Energy Recovery, Inc.ERIIFY2025
- ORASURE TECHNOLOGIES INCOSURFY2025
- Personalis, Inc.PSNLFY2025
- Quanterix CorpQTRXFY2025
- REPLIGEN CORPRGENFY2025
- RESEARCH FRONTIERS INCREFRFY2025
- STANDARD BIOTOOLS INC.LABFY2025
- TRANSCAT INCTRNSFY2026
- ZYNEX INCZYNXFY2024
- ZYNEX INCZYXIFY2024
Each company listed discloses MLAB in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named MLAB in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2026
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ATRC AtriCure, Inc.AZTA Azenta, Inc.CDXS Codexis, Inc.CYRX Cryoport, Inc.CTKB Cytek Biosciences, Inc.HAE Haemonetics CorporationINGN Inogen, Inc.LMAT LeMaitre Vascular, Inc.MRVI Maravai LifeSciences Holdings, Inc.NEOG Neogen CorporationNEO Neogenomics, Inc.QTRX Quanterix CorporationSHC Sotera Health, LLCVCYT Veracyte, Inc.LAB Standard BioTools, Inc.AORT Artivion, Inc.PACB Pacific Biosciences of California, Inc.BLFS BioLife Solutions, Inc.ADPT Adaptive Biotechnologies Corporation
Peer reciprocity
The companies Mesa Laboratories names as compensation peers that name it back in their own disclosed peer groups.
Cytek Biosciences, Inc. (CTKB)65Quanterix Corporation (QTRX)66Standard BioTools, Inc. (LAB)67BioLife Solutions, Inc. (BLFS)68Adaptive Biotechnologies Corporation (ADPT)69
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Haemonetics Corporation | 2026 | Christopher Simon | $1,100,008 | $7,561,987 | $1,504,968 | $1,834,250 | $12,044,701 |
| 2 | Sotera Health, LLC | 2025 | Michael Petras | 1,130,699 | 8,022,400 | 0 | 1,484,890 | 10,656,063 |
| 3 | Azenta, Inc. | 2025 | John Marotta | 900,000 | 8,386,297 | 0 | 1,063,656 | 10,371,414 |
| 4 | Maravai LifeSciences Holdings, Inc. | 2025 | Bernd Brust | 388,863 | 7,660,000 | 1,460,000 | 425,343 | 10,129,708 |
| 5 | AtriCure, Inc. | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 6 | Neogenomics, Inc. | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 7 | Adaptive Biotechnologies Corporation | 2025 | Chad Robins | 698,258 | 7,675,100 | 0 | 703,380 | 9,081,690 |
| 8 | Standard BioTools, Inc. | 2025 | Michael Egholm | 680,256 | 5,337,883 | 1,671,363 | 1,120,000 | 8,823,502 |
| 9 | Neogen Corporation | 2026 | Mike Nassif | 630,769 | 3,250,000 | 3,250,000 | 1,000,000 | 8,693,916 |
| 10 | Veracyte, Inc. | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 11 | BioLife Solutions, Inc. | 2024 | Roderick de Greef | 744,450 | 5,571,874 | 0 | 655,116 | 7,046,205 |
| 12 | Artivion, Inc. | 2025 | J. Patrick Mackin | 835,145 | 5,006,990 | 0 | 991,368 | 6,883,108 |
| 13 | Mesa Laboratories | 2026 | Gary Owens | 808,846 | 4,700,017 | 0 | 1,120,000 | 6,643,208 |
| 14 | Quanterix Corporation | 2025 | Masoud Toloue | 670,950 | 1,170,000 | 2,729,998 | 674,172 | 5,250,745 |
| 15 | Cytek Biosciences, Inc. | 2025 | Wenbin Jiang | 620,000 | 2,000,000 | 2,000,000 | 485,211 | 5,120,061 |
| 16 | Pacific Biosciences of California, Inc. | 2025 | Christian Henry | 748,250 | 1,151,013 | 1,696,278 | 714,305 | 4,309,846 |
| 17 | LeMaitre Vascular, Inc. | 2025 | George LeMaitre | 806,347 | 1,050,000 | 1,050,000 | 680,015 | 3,780,990 |
| 18 | Inogen, Inc. | 2025 | Kevin R.M. Smith | 711,077 | 1,874,550 | 0 | 0 | 2,613,804 |
| 19 | Cryoport, Inc. | 2025 | Jerrell Shelton | 967,845 | 192,300 | 306,869 | 908,510 | 2,375,524 |
| 20 | Codexis, Inc. | 2025 | Alison Moore | 524,732 | 255,994 | 1,065,223 | 463,125 | 2,323,279 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Mesa Laboratories | 125% | PSU 50 · RSU 50 | No | Frederic W. Cook & Co, Inc. |
| Adaptive Biotechnologies Corporation | not disclosed | RSU 50 · PSU 50 | not disclosed | Semler Brossy Consulting Group, LLC |
| Artivion, Inc. | 118.7% | PSU 50 · RSU 50 | No | Willis Towers Watson |
| AtriCure, Inc. | not disclosed | PSU 70 · RSU 30 | No | Korn Ferry |
| Azenta, Inc. | not disclosed | PSU 50 · RSU 50 | Yes — Relative TSR (rTSR) | Pearl Meyer |
| BioLife Solutions, Inc. | 88% | RSU 50 · Market-based RSU 50 | Yes — Total Shareholder Return (TSR) | Frederic W. Cook & Co, Inc. |
| Codexis, Inc. | 95% | not disclosed | not disclosed | Pearl Meyer |
| Cryoport, Inc. | 92.2% | not disclosed | not disclosed | Frederic W. Cook & Co., Inc. |
| Cytek Biosciences, Inc. | 78.4% | RSU 50 · Options 50 | not disclosed | Meridian Compensation Partners, LLC |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Inogen, Inc. | 60% | RSU 50 · PRSU 50 | No | Aon |
| LeMaitre Vascular, Inc. | not disclosed | Option 50 · RSU 25 · PSU 25 | No | not disclosed |
| Maravai LifeSciences Holdings, Inc. | not disclosed | not disclosed | No | Meridian Compensation Partners, LLC |
| Neogen Corporation | not disclosed | PSU 50 · Option 50 | not disclosed | Farient Advisors, LLC |
| Neogenomics, Inc. | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| Pacific Biosciences of California, Inc. | 95% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Quanterix Corporation | 95% | Options 70 · RSU 30 | not disclosed | PayGov |
| Sotera Health, LLC | 103% | PSU 40 · RSU 40 · Other 20 | No | Exequity, LLP |
| Standard BioTools, Inc. | 160% | not disclosed | not disclosed | Pearl Meyer |
| Veracyte, Inc. | 118% | PSU 50 · RSU 50 | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-09-08 | 4,317,389 | 136,782 | 80,326 | 96.93% | Passed |
| 2025 | 2025-08-22 | 4,476,544 | 275,297 | 134,659 | 91.61% | Passed |
| 2024 | 2024-08-30 | 4,581,083 | 226,773 | 33,030 | 94.63% | Passed |
| 2024 | 2024-08-30 | 4,581,083 | 226,773 | 33,030 | 94.63% | Passed |
| 2023 | 2023-08-25 | 4,414,163 | 188,692 | 151,168 | 92.85% | Passed |
| 2022 | 2022-08-26 | 1,039,445 | 3,046,595 | 296,881 | 23.72% | Failed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-09-08 | 96.93%a |
| 2025 | 2025-08-22 | 91.61%b |
| 2024 | 2024-08-30 | 94.63%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “An abstention will count as present for the purpose of determining the presence of a quorum but will have the effect of a vote against the proposal.”.
c. Approved under the standard stated in the filing — “An abstention will count as present for the purposes of determining the presence of a quorum but will have the effect of a vote against the proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 79 : 1 |
|---|---|
| CEO total compensation | $6,643,208 |
| Median employee compensation | $83,861 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2026 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Tony Tripeny | Director | 2026-08-13 | A | 900 | $114 | $102,321 | Common | Form 4 ↗ |
| Siddhartha Kadia | President and CEO | 2026-08-13 | A | 7,093 | 113 | 800,090 | Common, indirect | Form 4 ↗ |
| John Sullivan | Director | 2026-08-13 | D | 7,093 | 113 | 800,090 | Common | Form 4 ↗ |
| Shiraz Ladiwala | Director | 2026-08-15 | A | 3,810 | 0 | 0 | Common | Form 4 ↗ |
| John Sullivan | Director | 2026-08-15 | D | 2,784 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Sullivan | Director | 2026-08-15 | A | 2,784 | 0 | 0 | Common | Form 4 ↗ |
| Jennifer Alltoft | Director | 2026-08-15 | D | 2,784 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer Alltoft | Director | 2026-08-15 | A | 2,784 | 0 | 0 | Common | Form 4 ↗ |
| Mark Capone | Director | 2026-08-15 | A | 2,784 | 0 | 0 | Common | Form 4 ↗ |
| Tony Tripeny | Director | 2026-08-15 | A | 2,784 | 0 | 0 | Common | Form 4 ↗ |
| Shannon Hall | Director | 2026-08-15 | A | 2,784 | 0 | 0 | Common | Form 4 ↗ |
| Shiraz Ladiwala | Director | 2026-08-15 | D | 3,810 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Capone | Director | 2026-08-15 | D | 2,784 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Hall | Director | 2026-08-15 | D | 2,784 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tony Tripeny | Director | 2026-08-15 | D | 2,784 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-09 | — | 5,322 | — | — | 3 insiders, 3 accrual rows | ||
| Shiraz Ladiwala | Director | 2026-09-09 | A | 2,510 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Capone | Director | 2026-09-09 | A | 2,423 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Sullivan | Director | 2026-10-13 | D | 1,200 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 21 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Tony Tripeny | Director | 2026-08-13 | A | 900 | $114 | $102,321 | Common | Form 4 ↗ |
| Siddhartha Kadia | President and CEO | 2026-08-13 | A | 7,093 | 113 | 800,090 | Common, indirect | Form 4 ↗ |
| John Sullivan | Director | 2026-08-13 | D | 7,093 | 113 | 800,090 | Common | Form 4 ↗ |
| Shiraz Ladiwala | Director | 2026-08-15 | A | 3,810 | 0 | 0 | Common | Form 4 ↗ |
| John Sullivan | Director | 2026-08-15 | D | 2,784 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Sullivan | Director | 2026-08-15 | A | 2,784 | 0 | 0 | Common | Form 4 ↗ |
| Jennifer Alltoft | Director | 2026-08-15 | D | 2,784 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer Alltoft | Director | 2026-08-15 | A | 2,784 | 0 | 0 | Common | Form 4 ↗ |
| Mark Capone | Director | 2026-08-15 | A | 2,784 | 0 | 0 | Common | Form 4 ↗ |
| Tony Tripeny | Director | 2026-08-15 | A | 2,784 | 0 | 0 | Common | Form 4 ↗ |
| Shannon Hall | Director | 2026-08-15 | A | 2,784 | 0 | 0 | Common | Form 4 ↗ |
| Shiraz Ladiwala | Director | 2026-08-15 | D | 3,810 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Capone | Director | 2026-08-15 | D | 2,784 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Hall | Director | 2026-08-15 | D | 2,784 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tony Tripeny | Director | 2026-08-15 | D | 2,784 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tony Tripeny | Director | 2026-09-09 | A | 1,774 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shiraz Ladiwala | Director | 2026-09-09 | A | 2,510 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Capone | Director | 2026-09-09 | A | 2,423 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Sullivan | Director | 2026-09-09 | A | 1,774 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shannon Hall | Director | 2026-09-09 | A | 1,774 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Sullivan | Director | 2026-10-13 | D | 1,200 | 0 | 0 | Common | Form 4 ↗ |
Sources (69 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Gary Owens. DEF 14A, filed 2026-07-22. Section “Summary Compensation Table” · page 51. As printed: 6,643,208. View filing ↗
- Section 01, John Sakys. DEF 14A, filed 2026-07-22. Section “Summary Compensation Table”. As printed: 2,471,543. View filing ↗
- Section 01, Brian Archbold. DEF 14A, filed 2026-07-22. Section “Summary Compensation Table”. As printed: 2,182,518. View filing ↗
- Section 03, John Sakys PSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Gary Owens PSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Gary Owens RSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Archbold RSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, John Sakys RSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Archbold PSU. DEF 14A, filed 2026-07-22. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-07-22. Section “CEO Pay Ratio”. As printed: 79 : 1. View filing ↗
- Section 08, John Sullivan. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 295,000. View filing ↗
- Section 08, Jennifer Alltoft. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 260,000. View filing ↗
- Section 08, Tony Tripeny. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 260,000. View filing ↗
- Section 08, Mark Capone. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 260,000. View filing ↗
- Section 08, Shiraz Ladiwala. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 260,000. View filing ↗
- Section 08, Shannon Hall. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 250,000. View filing ↗
- Section 08, Siddhartha Kadia. DEF 14A, filed 2026-07-22. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Tony Tripeny 2026-08-13. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Siddhartha Kadia 2026-08-13. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Sullivan 2026-08-13. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shiraz Ladiwala 2026-08-15. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Sullivan 2026-08-15. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Sullivan 2026-08-15. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jennifer Alltoft 2026-08-15. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jennifer Alltoft 2026-08-15. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Capone 2026-08-15. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tony Tripeny 2026-08-15. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shannon Hall 2026-08-15. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shiraz Ladiwala 2026-08-15. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Capone 2026-08-15. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shannon Hall 2026-08-15. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tony Tripeny 2026-08-15. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tony Tripeny 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shiraz Ladiwala 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mark Capone 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Sullivan 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shannon Hall 2026-09-09. Form 4, filed 2026-09-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Sullivan 2026-10-13. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-09-08. Item 5.07 · say-on-pay result. As reported: 96.93% (votes for as printed: 4,317,389). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-08-25. Item 5.07 · say-on-pay result. As reported: 91.61% (votes for as printed: 4,476,544). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-08-30. Item 5.07 · say-on-pay result. As reported: 94.63%. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 375,000 + equity 1,210,000 + all other 0 = 1,585,000, summed across the director compensation table rows.
- Haemonetics Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-09. CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. View filing ↗
- Sotera Health, LLC, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Sotera Health, LLC's own proxy. As printed: 10,656,063. View filing ↗
- Azenta, Inc., Section 10b CEO total. DEF 14A, filed 2025-12-18. CEO total compensation as printed in Azenta, Inc.'s own proxy. As printed: 10,371,414. View filing ↗
- Maravai LifeSciences Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Maravai LifeSciences Holdings, Inc.'s own proxy. As printed: 10,129,708. View filing ↗
- AtriCure, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. View filing ↗
- Neogenomics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Neogenomics, Inc.'s own proxy. As printed: 9,127,092. View filing ↗
- Adaptive Biotechnologies Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Adaptive Biotechnologies Corporation's own proxy. As printed: 9,081,690. View filing ↗
- Standard BioTools, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Standard BioTools, Inc.'s own proxy. As printed: 8,823,502. View filing ↗
- Neogen Corporation, Section 10b CEO total. DEF 14A, filed 2026-08-21. CEO total compensation as printed in Neogen Corporation's own proxy. As printed: 8,693,916. View filing ↗
- Veracyte, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. View filing ↗
- BioLife Solutions, Inc., Section 10b CEO total. DEF 14A, filed 2025-07-08. CEO total compensation as printed in BioLife Solutions, Inc.'s own proxy. As printed: 7,046,205. View filing ↗
- Artivion, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Artivion, Inc.'s own proxy. As printed: 6,883,108. View filing ↗
- Mesa Laboratories (subject), Section 10b CEO total. DEF 14A, filed 2026-07-22. CEO total compensation as printed in Mesa Laboratories's own proxy. As printed: 6,643,208. View filing ↗
- Quanterix Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Quanterix Corporation's own proxy. As printed: 5,250,745. View filing ↗
- Cytek Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cytek Biosciences, Inc.'s own proxy. As printed: 5,120,061. View filing ↗
- Pacific Biosciences of California, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Pacific Biosciences of California, Inc.'s own proxy. As printed: 4,309,846. View filing ↗
- LeMaitre Vascular, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in LeMaitre Vascular, Inc.'s own proxy. As printed: 3,780,990. View filing ↗
- Inogen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Inogen, Inc.'s own proxy. As printed: 2,613,804. View filing ↗
- Cryoport, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Cryoport, Inc.'s own proxy. As printed: 2,375,524. View filing ↗
- Codexis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Codexis, Inc.'s own proxy. As printed: 2,323,279. View filing ↗
- Section 10a, Cytek Biosciences, Inc. reciprocity. DEF 14A. Cytek Biosciences, Inc. names Mesa Laboratories in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Quanterix Corporation reciprocity. DEF 14A. Quanterix Corporation names Mesa Laboratories in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Standard BioTools, Inc. reciprocity. DEF 14A. Standard BioTools, Inc. names Mesa Laboratories in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, BioLife Solutions, Inc. reciprocity. DEF 14A. BioLife Solutions, Inc. names Mesa Laboratories in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Adaptive Biotechnologies Corporation reciprocity. DEF 14A. Adaptive Biotechnologies Corporation names Mesa Laboratories in its own disclosed peer group (read from its most recent proxy). View filing ↗